Ushbu ish iqtibos qilgan ishlar

32 ta ish

Ish: Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan—A Retrospective Cohort Study

1. Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures

   Helen Cox, Stobdan Kalon, Sholpan Allamuratova +6

   MaqolaOAOchiq kirish200713 iqtibos

   ABIABI:AkademIndex/2026.other.163905

2. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

   Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos

   ABIABI:AkademIndex/2022.article.000002

3. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

   Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei +35

   Sharh maqolaOAOchiq kirish20204 iqtibos

   ABIABI:AkademIndex/2026.other.006851

4. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

   Parvati Nair, T. Hasan, K. K. Zaw +9

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20224 iqtibos

   ABIABI:AkademIndex/2026.other.281624

5. Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

   Andreas H. Diacon, Peter R. Donald, Alexander S. Pym +11

   MaqolaOAOchiq kirish20123 iqtibos

   ABIABI:AkademIndex/2026.other.185768

6. Sarlavhasiz

   Boshqa2 iqtibos

   ABIABI:AkademIndex/2026.other.034198

7. Sarlavhasiz

   BoshqaOAOchiq kirish2 iqtibos

   ABIABI:AkademIndex/2026.other.133238

8. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

   S. Moe, M. L. Rekart, D. Hernandez +9

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20232 iqtibos

   ABIABI:AkademIndex/2026.other.281628

9. Sarlavhasiz

   Boshqa2 iqtibos

   ABIABI:AkademIndex/2026.other.388502

10. Sarlavhasiz

    Boshqa2 iqtibos

    ABIABI:AkademIndex/2026.other.504210

11. Sarlavhasiz

    Boshqa2 iqtibos

    ABIABI:AkademIndex/2026.other.944248

12. Sarlavhasiz

    Boshqa2 iqtibos

    ABIABI:AkademIndex/2026.other.944250

13. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

    S. Moe, I. Azamat, Sholpan Allamuratova +14

    MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyIJTLD OPEN20241 iqtibos

    ABIABI:AkademIndex/2024.article.001030

14. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

    Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

    MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyClinical Infectious Diseases20251 iqtibos

    ABIABI:AkademIndex/2025.article.000230

15. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944235

16. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944236

17. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944237

18. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944238

19. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944239

20. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944240

21. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944241

22. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944242

23. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944243

24. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944244

25. Sarlavhasiz

    Boshqa1 iqtibos

    ABIABI:AkademIndex/2026.other.944245